Citation: Cw. Cranor et al., REPLACEMENT OF DIVALPROEX SODIUM WITH VALPROIC ACID NOT CLEAR-CUT - REPLY, American journal of health-system pharmacy, 55(10), 1998, pp. 1073-1073
Citation: C. Lindley et al., QUALITY-OF-LIFE AND PREFERENCES FOR TREATMENT FOLLOWING SYSTEMIC ADJUVANT THERAPY FOR EARLY-STAGE BREAST-CANCER, Journal of clinical oncology, 16(4), 1998, pp. 1380-1387
Citation: Cw. Cranor et al., CLINICAL AND ECONOMIC-IMPACT OF REPLACING DIVALPROEX SODIUM WITH VALPROIC ACID, American journal of health-system pharmacy, 54(15), 1997, pp. 1716-1722
Authors:
PECKMAN HJ
DUPUIS RE
SAWYER WT
BROUWER KLR
CROSS RE
Citation: Hj. Peckman et al., VANCOMYCIN SERUM CONCENTRATIONS IN PATIENTS WITH RENAL DYSFUNCTION - A COMPARISON OF FLUORESCENCE POLARIZATION IMMUNOASSAY AND THE ENZYME-MULTIPLIED IMMUNOASSAY TECHNIQUE, Therapeutic drug monitoring, 18(6), 1996, pp. 647-653
Authors:
GUNNARSSON PS
SAWYER WT
MONTAGUE D
WILLIAMS ML
DUPUIS RE
CAIOLA SM
Citation: Ps. Gunnarsson et al., APPROPRIATE USE OF HEPARIN - EMPIRIC VS NOMOGRAM-BASED DOSING, Archives of internal medicine, 155(5), 1995, pp. 526-532
Authors:
LINDLEY CM
SAWYER WT
MACIK BG
LUSHER J
HARRISON JF
BAIRDCOX K
BIRCH K
GLAZER S
ROBERTS HR
Citation: Cm. Lindley et al., PHARMACOKINETICS AND PHARMACODYNAMICS OF RECOMBINANT FACTOR VIIA, Clinical pharmacology and therapeutics, 55(6), 1994, pp. 638-648
Authors:
MACIK BG
LINDLEY CM
LUSHER J
SAWYER WT
BLOOM AL
HARRISON JF
BAIRDCOX K
BIRCH K
GLAZER S
ROBERTS HR
Citation: Bg. Macik et al., SAFETY AND INITIAL CLINICAL EFFICACY OF 3 DOSE LEVELS OF RECOMBINANT ACTIVATED FACTOR-VII (RFVIIA) - RESULTS OF A PHASE-I STUDY, Blood coagulation & fibrinolysis, 4(4), 1993, pp. 521-527
Authors:
JOHANSEN L
BUCHER D
HANSEN LL
KASTBERG H
LINDLEY C
MADSEN P
SAWYER WT
Citation: L. Johansen et al., RELATION BETWEEN FACTOR-VIIA COAGULANT ACTIVITY AND PT AND BETWEEN FACTOR-VIIA COAGULANT ACTIVITY AND APTT IN HUMAN PLASMA, Thrombosis and haemostasis, 69(6), 1993, pp. 1125-1125